Crossover trials are clinical experiments in which participants are assigned randomly to a sequence of treatments and each participant serves as his/her own control in estimating the treatments’ effect.

The advantage of crossover is that it effectively doubles the number of people in a trial which makes it easier to obtain statistically significant results more quickly, and participants act as their own control since their data is analyzed by comparing participants to themselves – before the intervention and after each intervention period.

Essentially, the study participants are switched through the treatment groups (both test and reference formulations) after a washout period. This gives a greater set of results with fewer volunteers and in a more controlled way.

QUINTA-ANALYTICA who are experts in this approach go a step further and plan and design studies so that the washout period of one study is utilized as a confinement period for another. Combine this with the fact they’ve smartly constructed their clinical unit in two independent parts to allow for simultaneous studies, the outcome is an impressive set of quality results in a very short period.

Ready to start your next cross-over Bioavailability or Bioequivalence study? Get in touch!

Additional News

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.